Processing

Please wait...

Settings

Settings

Goto Application

1. WO2002020047 - CHLAMYDIAL PEPTIDES AND THEIR MIMICS IN DEMYELINATING DISEASE

Publication Number WO/2002/020047
Publication Date 14.03.2002
International Application No. PCT/US2001/027533
International Filing Date 06.09.2001
Chapter 2 Demand Filed 05.04.2002
IPC
A61K 38/11 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
10Peptides having 12 to 20 amino acids
11Oxytocins; Vasopressins; Related peptides
A61K 39/00 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
A61K 39/118 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
118Chlamydiaceae, e.g. Chlamydia trachomatis or Chlamydia psittaci
A61K 47/48 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
48the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
A61K 49/00 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
49Preparations for testing in vivo
C07K 14/295 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
195from bacteria
295from Chlamydiales (O)
CPC
A01K 2217/05
AHUMAN NECESSITIES
01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
KANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
2217Genetically modified animals
05Animals comprising random inserted nucleic acids (transgenic)
A61K 2039/5156
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
51comprising whole cells, viruses or DNA/RNA
515Animal cells
5156expressing foreign proteins
A61K 38/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
A61K 39/0008
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
0005Vertebrate antigens
0008Antigens related to auto-immune diseases; Preparations to induce self-tolerance
A61K 39/118
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
118Chlamydiaceae, e.g. Chlamydia trachomatis or Chlamydia psittaci
A61K 47/62
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
50the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
51the non-active ingredient being a modifying agent
62the modifying agent being a protein, peptide or polyamino acid
Applicants
  • WAYNE STATE UNIVERSITY [US]/[US] (AllExceptUS)
  • SWANBORG, Robert, H. [US]/[US] (UsOnly)
  • LENZ, Derek, C. [US]/[US] (UsOnly)
  • HUDSON, Alan, P. [US]/[US] (UsOnly)
  • WHITTUM-HUDSON, Judith, A. [US]/[US] (UsOnly)
Inventors
  • SWANBORG, Robert, H.
  • LENZ, Derek, C.
  • HUDSON, Alan, P.
  • WHITTUM-HUDSON, Judith, A.
Agents
  • LIVNAT, Shmuel
Priority Data
60/230,45306.09.2000US
60/301,86002.07.2001US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) CHLAMYDIAL PEPTIDES AND THEIR MIMICS IN DEMYELINATING DISEASE
(FR) PEPTIDES DE CHLAMYDIOSE ET LEURS MIMIQUES DANS UNE AFFECTION DEMYELINISANTE
Abstract
(EN)
Subsequent to reports that Chlamydia pneumoniae (Cpn) was present in the CSF of a subset of multiple sclerosis (MS) patients, a 20-mer peptide from a protein specific to C. pneumoniae (Cpn) which shares a seven amino acid motif with a critical epitope of myelin basic protein (MBP), a major central nervous system antigen targeted by the autoimmune response in MS was identified. This bacterial peptide induces a Th1 response accompanied by severe clinical and histological experimental autoimmune encephalomyelitis in Lewis rats, a condition closely reflective of many aspects of MS. Various non-encephalitogenic peptide analogues ad derivatives are disclosed and are useful for inhibiting such Th1 responses, including protective Th2 responses, and for treating a subject having MS or delaying onset of preventing MS in a subject at risk.
(FR)
Suite à des rapports statuant que <i>Chlamydia pneumoniae</i> (Cpn) était présente dans le CSF d'un sous-ensemble de patients souffrant de sclérose en plaques, on a identifié un peptide 20-mer à partir d'une protéine spécifique de <i>C. pneumoniae</i> (Cpn) qui partage un motif à sept acides aminés avec un épitope crucial de la protéine de base de myéline (MBP), un important antigène du système nerveux central ciblé par la réponse auto-immune de la sclérose en plaques. Ce peptide bactérien induit une réponse Th1 accompagnée par une encéphalomyélite auto-immune expérimentale histologique et clinique chez des rats Lewis, une condition qui reflète étroitement plusieurs aspects de la sclérose en plaques. Cette invention concerne également divers dérivés et analogues de peptides non encéphalitogéniques, ainsi que leur utilisation dans l'inhibition des réponses Th1, y compris les réponses Th2 protectrices, et dans le traitement d'un sujet souffrant de sclérose en plaques ou dans le retardement du début de la prévention de la sclérose en plaques chez un sujet à risques.
Also published as
Latest bibliographic data on file with the International Bureau